Featured Research

from universities, journals, and other organizations

Most Ongoing Diabetes Trials Do Not Include Outcomes Important To Patients

Date:
June 3, 2008
Source:
JAMA and Archives Journals
Summary:
An analysis of ongoing randomized clinical trials (RCTs) in diabetes finds that only about 20 percent have as primary outcomes results that patients consider important, such as illness, pain, effect on function and death, according to a new study.

An analysis of ongoing randomized clinical trials (RCTs) in diabetes finds that only about 20 percent have as primary outcomes results that patients consider important, such as illness, pain, effect on function and death, according to a new study. Concerns about the safety and efficacy of diabetes interventions continue, in part because RCTs have not measured their effect on patient-important outcomes as quality of life and death, according to background information in the article. "Are future diabetes trials likely to be more informative to patients and clinicians?" the researchers ask.

Gunjan Y. Gandhi, M.D., M.Sc., and M. Hassan Murad, M.D., M.P.H., of Mayo Clinic, Rochester, Minn., and colleagues examined large public clinical trial registries to systematically determine the extent to which ongoing and future registered RCTs plan to measure patient-important outcomes in patients with diabetes. The researchers identified phase 2 through 4 RCTs enrolling patients with diabetes. Of 2,019 RCTs, 1,054 proved eligible, and 50 percent of these (527) were randomly sampled, and 436 trials registered since registration became mandatory in 2004 were selected. Of these, 6 percent (24) had not started enrollment, 25 percent (109) were actively enrolling, and 69 percent (303) had completed enrollment.

Reviewers collected study characteristics and determined the outcomes measured and their type (physiological outcomes [insulin, C-peptide levels], surrogate outcomes thought to reflect an increased risk for patient-important outcomes [such as cholesterol levels, worsening kidney function], and patient-important outcomes [illness, pain, function and death]).

The researchers found that primary outcomes were patient-important outcomes in 18 percent of the RCTs, physiological and laboratory outcomes in 16 percent, and surrogate outcomes in 61 percent of the 436 RCTs. Patient-important outcomes were reported as primary or secondary outcomes in 46 percent of the RCTs.

Independent predictors of patient-important outcomes were larger trial size and longer trial duration while trials of patients with type 2 diabetes were significantly less likely to report patient-important outcomes as a primary outcome. For primary and secondary outcomes, predictors of patient-important outcomes were trial length and trial phase (phase 3 or 4 vs. phase 2), with trials of patients with type 2 diabetes significantly less likely to report patient-important outcomes.

The authors write, "... the importance of our findings is that (1) without pooling, the individual diabetes trials will largely fail in providing information about the effect of interventions on patient-important outcomes; and (2) trials that are planning to measure patient-important outcomes as secondary end points need to overcome the temptation to selectively report outcomes with statistically significant results as well as to report these findings transparently and carefully. Journals also may need to publish the less-than-interesting results to enable meta-analyses of these results to produce precise enough estimates that can guide practice.

"We believe the time has come for a broad consensus on a standard set of important outcomes for patients in diabetes trials, similar to the Outcome Measures in Rheumatology (OMERACT) initiative. The OMERACT approach allows for the uniform measurement of outcomes in RCTs with emphasis on outcomes that experts--and ultimately patients--thought would better capture the experience of rheumatological conditions."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gunjan Y. Gandhi; M. Hassan Murad; Akira Fujiyoshi; Rebecca J. Mullan; David N. Flynn; Mohamed B. Elamin; Brian A. Swiglo; William L. Isley; Gordon H. Guyatt; Victor M. Montori. Patient-Important Outcomes in Registered Diabetes Trials. JAMA, 2008;299(21):2543-2549 [link]

Cite This Page:

JAMA and Archives Journals. "Most Ongoing Diabetes Trials Do Not Include Outcomes Important To Patients." ScienceDaily. ScienceDaily, 3 June 2008. <www.sciencedaily.com/releases/2008/06/080603164356.htm>.
JAMA and Archives Journals. (2008, June 3). Most Ongoing Diabetes Trials Do Not Include Outcomes Important To Patients. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/06/080603164356.htm
JAMA and Archives Journals. "Most Ongoing Diabetes Trials Do Not Include Outcomes Important To Patients." ScienceDaily. www.sciencedaily.com/releases/2008/06/080603164356.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins